| Name | Title | Contact Details |
|---|
Established in January, 2000, following the consolidation of St. Elizabeth Hospital and Elizabeth General Medical Center, Trinitas Regional Medical Center is a full-service healthcare facility serving those who live and work in Eastern and Central Union County. Operating on two major campuses, Trinitas Regional Medical Center has 554 beds, including a 120-bed long-term care center. Trinitas Regional Medical Center is proud to offer state-of-the-art medicine backed by compassion and competence. Our friendly, professional staff and skilled physicians are the foundation of the care we provide. Together, our medical team offers the community the most advanced technological care in every area of medicine and surgery. Utilizing a full spectrum of sophisticated inpatient, outpatient and long-term care services, Trinitas Regional Medical Center is proud to have forged a lifelong partnership with families, physicians and communities to provide the best care in a supportive and caring environment. We treat over 17,000 inpatients annually, 70,000 emergency patients, and several hundred thousand outpatients. Trinitas Regional Medical Center is pleased to offer a number of Centers of Excellence and specialized major services, including Behavioral Health,Bloodless Medicine, Cancer Care, Cardiology, Diabetes Management,Maternal and Child Health, Renal Services, School of Nursing, Senior Services, Sleep Disorders, Women`s Services, Wound Healing and more. A Catholic teaching hospital, Trinitas Regional Medical Center is sponsored by the Sisters of Charity of Saint Elizabeth in partnership with Elizabethtown Healthcare Foundation.
Global Marketing Resources Inc is a Dunedin, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Reliq Health Technologies is a Vancouver, BC based healthcare technology company that specializes in developing innovative, secure mobile software solutions for the $20 Billion Community Care market. Reliq`s iUGO Health technology platform is a comprehensive hardware and software solution that allows complex patients to receive high quality care in the home, improving health outcomes, enhancing quality of life for patients & families and reducing the cost of care delivery.
Athens Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Athens Regional Medical Center is based in Athens, GA. You can find more information on Athens Regional Medical Center at www.armc.org
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.